| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1989PNAS...86.1382B |
| P356 | DOI | 10.1073/PNAS.86.4.1382 |
| P932 | PMC publication ID | 286694 |
| P698 | PubMed publication ID | 2784006 |
| P5875 | ResearchGate publication ID | 20372251 |
| P2093 | author name string | U Hedner | |
| J B Garris | |||
| K M Brinkhous | |||
| M S Read | |||
| V Diness | |||
| P2860 | cites work | Tissue factor and hemostasis | Q28630773 |
| Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells | Q28646327 | ||
| Characterization of a cDNA coding for human factor VII | Q28646329 | ||
| Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation | Q33647003 | ||
| Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure | Q34232161 | ||
| Purification and properties of human coagulation factor VII. | Q34285207 | ||
| Prevention of occlusive coronary artery thrombosis by a murine monoclonal antibody to porcine von Willebrand factor | Q34366855 | ||
| An alternative extrinsic pathway of human blood coagulation. | Q34715607 | ||
| Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation | Q35047906 | ||
| Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors | Q36990492 | ||
| Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs | Q37559120 | ||
| Tissue factor-initiated blood coagulation | Q40168938 | ||
| Tissue factor revisited. | Q40253416 | ||
| Pathophysiology of platelet-aggregating von Willebrand factor: applications of the venom coagglutinin vWF assay | Q40312861 | ||
| Altered factor VII activity in hemophilia | Q41495913 | ||
| Activated factor VII: presence in factor IX concentrates and persistence in the circulation after infusion | Q41545752 | ||
| The inhibition of activated bovine coagulation factors X and VII by antithrombin III. | Q43458224 | ||
| Initiation of the extrinsic pathway of coagulation. Association of factor VIIa with a cell line expressing tissue factor | Q43658573 | ||
| The esterase activity of coagulation factor VII. Evidence for intrinsic activity of the zymogen | Q44691907 | ||
| Expression and linkage of genes for X-linked hemophilias A and B in the dog | Q45856212 | ||
| Activated prothrombin concentrate for patients with factor VIII inhibitors | Q45856551 | ||
| Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial | Q45863685 | ||
| A canine model of hemophilic (factor VIII:C deficiency) bleeding | Q45864385 | ||
| An inhibitory monoclonal antibody against human tissue factor | Q48224968 | ||
| Monoclonal antibodies against bovine tissue factor, which block interaction with factor VIIa. | Q48478286 | ||
| Interaction of tissue factor and factor VII at the earliest phase of coagulation | Q51261558 | ||
| The effect of antithrombin III on the activity of the coagulation factors VII, IX and X | Q66705587 | ||
| Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds | Q68273350 | ||
| Effect of calcium ion concentration on the ability of fibrinogen and von Willebrand factor to support the ADP-induced aggregation of human platelets | Q68826461 | ||
| von Willebrand disease | Q70321843 | ||
| The development and characterisation of antibodies to human factor VIII in haemophilic dogs | Q70361308 | ||
| Venom coagglutinin for detection of von Willebrand factor activity in animal plasmas | Q70981710 | ||
| Use of venom coagglutinin and lyophilized platelets in testing for platelet-aggregating von Willebrand factor | Q72073463 | ||
| Ethanol Gelation: A Rapid Screening Test for Intravascular Coagulation | Q72229166 | ||
| Determination of fibrinogen and fibrinogenolytic activity | Q79452693 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hemophilia | Q134003 |
| hemophilia A | Q2092064 | ||
| hemophilia B | Q2562598 | ||
| P304 | page(s) | 1382-1386 | |
| P577 | publication date | 1989-02-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease | |
| P478 | volume | 86 |
| Q30442996 | A review of current methods for assessing hemostasis in vivo and introduction to a potential alternative approach |
| Q30443003 | ARFI ultrasound monitoring of hemorrhage and hemostasis in vivo in canine von Willebrand disease and hemophilia |
| Q45877085 | Activated factor VII: my story |
| Q38235951 | Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomes |
| Q27012571 | Animal models of hemophilia |
| Q37091290 | Animal models of hemophilia and related bleeding disorders |
| Q34326780 | Canine hemophilia B resulting from a point mutation with unusual consequences |
| Q45889662 | Change of antigenic and neutralizing specificity in substitutional epitope peptides of hemophilia B inhibitor |
| Q45859525 | Characterization of canine coagulation factor VII and its complex formation with tissue factor: canine-human cross-species compatibility. |
| Q33584641 | Clinical use of recombinant FVIIa (rFVIIa). |
| Q37332201 | Complications of hemophilia A treatment: factor VIII inhibitors |
| Q45866368 | Epitope mapping of human factor IX inhibitor antibodies |
| Q45866981 | Gene Therapy for Hemophilia B: Host Immunosuppression Prolongs the Therapeutic Effect of Adenovirus-Mediated Factor IX Expression |
| Q36337979 | Global measurement of coagulation in plasma from normal and haemophilia dogs using a novel modified thrombin generation test - Demonstrated in vitro and ex vivo |
| Q45865821 | In vivo bypass of hemophilia A coagulation defect by factor XIIa implant |
| Q35109095 | In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs |
| Q37056724 | In vivo models of haemophilia - status on current knowledge of clinical phenotypes and therapeutic interventions |
| Q43615162 | Induction of acquired factor IX inhibitors in cynomolgus monkey (Macaca fascicularis): a new primate model of hemophilia B. |
| Q37570030 | Intravascular inhibition of factor VIIa and the analogue NN1731 by antithrombin. |
| Q30409863 | Lessons Learned from Animal Models of Inherited Bleeding Disorders |
| Q33802667 | Long-term expression of canine FVIIa in hemophilic dogs |
| Q36532500 | Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality |
| Q37277251 | N-/O-glycosylation analysis of human FVIIa produced in the milk of transgenic rabbits |
| Q37778292 | Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients |
| Q37586365 | Pharmacokinetics, pharmacodynamics and safety of recombinant canine FVIIa in a study dosing one haemophilia A and one haemostatically normal dog. |
| Q42139651 | Poly-N-acetylglucosamine fibers amplify the effectiveness of recombinant factor VIIA on clot formation in hemophilia B canine blood |
| Q36284643 | Preclinical trauma studies of recombinant factor VIIa |
| Q33490246 | Preservation of hemostatic and structural properties of rehydrated lyophilized platelets: potential for long-term storage of dried platelets for transfusion |
| Q35006608 | Prevention of spontaneous bleeding in dogs with haemophilia A and haemophilia B. |
| Q45881284 | Prolonged recombinant activated factor VII (rFVIIa) treatment for severe bleeding in a factor-IX-deficient patient with an inhibitor |
| Q35006603 | Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency |
| Q40901543 | Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. |
| Q38527508 | Recombinant activated factor VII: 30 years of research and innovation |
| Q34078730 | Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model |
| Q39262923 | Ribavirin-induced intracellular GTP depletion activates transcription elongation in coagulation factor VII gene expression. |
| Q37162830 | Successful treatment of canine hemophilia by continuous expression of canine FVIIa |
| Q30745198 | The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion |
| Q33982533 | The diagnosis, management, and postnatal prevention of intraventricular hemorrhage in the preterm neonate |
| Q39611127 | The influence of coagulation and inflammation research on the improvement of polytrauma care |
| Q38176103 | Traumatic coagulopathy--part 2: Resuscitative strategies |
| Q90858007 | Treatment and prevention of bleeding in congenital hemophilia A patients with inhibitors |
Search more.